FDA Approves Biosimilar to Etanercept
Etanercept-szzs (Erelzi, Sandoz) has been approved by the U.S. Food and Drug Administration for RA and more.
Lessons from the “Biosimilarized”
A new report confirms that discounts for biosimilars do not determine global uptake and prescription incentives to encourage the use of biosimilars are hit and miss.
FDA Committee Recommends Two Biosimilars
Biosimilars to Humira and Enbrel are one step closer to the marketplace with FDA advisory committee approval.
Biosimilar Confidence: Patient Perspectives on a New Medication Class
Global Healthy Living Foundation and CreakyJoints president and co-founder, Seth Ginsberg, cautions against extrapolation, but is optimistic about biosimilars.
Biosimilar Switching Not for All Remicade Patients
ARD study recommends against biosimilar switching for patients positive for anti-infliximab (Remicade) antibodies.
Approved Indications for Biosimilar Inflectra
In this slideshow, we summarize the approved indications for the rheumatology biosimilar Inflectra (infliximab-dyyb), the boxed warnings and possible side effects.
Challenges Ahead for Newly Approved Biosimilar Inflectra
The U.S. approval of the first biosimilar in rheumatology, Inflectra, has been welcome news. Still, concerns about safety, interchangeability and costs dominate the discussions.
By clicking Accept, you agree to become a member of the UBM Medica Community.